 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, developer of the Phase 3 clinical trial M001 universal influenza vaccine candidate, today announced that the Annual General Meeting of Shareholders of the Company will be held on September 2, 2020 in Tel Aviv, Israel. Details, including a link to the Proxy Statement and voting card, are available on the SEC website at Shareholders are invited to contact their broker for voting procedures. Note that votes must be received prior to the deadline noted on the proxy. 